WAYMADE PLC — Citalopram Importer Profile
Pharmaceutical Importer · #12 buyer for Citalopram · $2.6M import value · 64 shipments · UNITED KINGDOM · DGFT Verified
WAYMADE PLC is the #12 importer of Citalopram from India with $2.6M in import value and 64 verified shipments. WAYMADE PLC holds a 1.3% market share in Citalopram imports based in UNITED KINGDOM. The company sources from 1 verified supplier across 55 formulations shipped to 1 country. Overall, WAYMADE PLC imports 2 pharmaceutical products worth $4.2M across 2 therapeutic categories.
WAYMADE PLC — Citalopram Import Profile: Suppliers, Formulations & Sources
Who Actually Supplies Citalopram to WAYMADE PLC?
Verified from 64 customs shipment records
| Supplier | Value | Shipments | % Share |
|---|---|---|---|
| GALPHA LABORATORIES LIMITED | $2.6M | 64 | 100.0% |
WAYMADE PLC sources Citalopram from 1 verified Indian supplier based on 64 customs records. The primary supplier is GALPHA LABORATORIES LIMITED accounting for 100.0% of imports.
How Does WAYMADE PLC Compare to Nearest Citalopram Importers?
Buyers ranked immediately above and below #12 by import value
| # | Buyer | Country | Import Value | Shipments | Avg/Shipment |
|---|---|---|---|---|---|
| 6 | M/S. RANBAXY FARMACEUTICA LTDA : | BRAZIL | $3.5M | 71 | $50.0K |
| 11 | MYLAN PHARMACEUTICALS INC, | UNITED STATES | $3.5M | 75 | $47.0K |
| 12 | WAYMADE PLC ★ | UNITED KINGDOM | $3.2M | 64 | $50.0K |
| 13 | RISING PHARMA HOLDINGS, INC. | UNITED STATES | $3.1M | 174 | $18.0K |
| 10 | AUROLOGISTICS LLC | UNITED STATES | $3.0M | 60 | $50.0K |
WAYMADE PLC ranks #12 among 736 Citalopram importers from India. Average shipment value of $50.0K compared to the market average of $74.5K. The closest competitors by value are M/S. RANBAXY FARMACEUTICA LTDA : and MYLAN PHARMACEUTICALS INC,.
Where Does WAYMADE PLC Import Citalopram To?
Destination countries from 64 verified shipments
| Country | Value | Shipments | Share |
|---|---|---|---|
| UNITED KINGDOM | $2.6M | 64 | 100.0% |
WAYMADE PLC imports Citalopram to 1 country. The primary destination is UNITED KINGDOM receiving 100.0% of shipments worth $2.6M.
What Citalopram Formulations Does WAYMADE PLC Import?
| Formulation | Value | Shipments |
|---|---|---|
| CITALOPRAM TABLETS 10MG,BATCH NOS.ET2300 | $150.0K | 3 |
| CITALOPRAM TABLETS 20MG,BATCH NOS.ET2301 | $100.0K | 2 |
| CITALOPRAM TABLETS 40MG,BATCH NOS.ET2302 | $100.0K | 2 |
| CITALOPRAM TABLETS 20MG BATCH NO.ET23204 TO ET23208 MFG.DT.JUL-2023 EXP.DT.JUN-2028 | $100.0K | 2 |
| CITALOPRAM TABLETS 20 MG BATCH NO.ET23320 TO 23324 MFG.DT.NOV-2023,EXP.DT.OCT-2028 (PACK-2 SX14 T)NOS | $83.6K | 3 |
| CITALOPRAM TABLETS 40MG,BATCH NOS.ET2301 | $58.0K | 2 |
| CITALOPRAM TABLETS 10MG,BATCH NOS.ET2301 | $57.8K | 2 |
| CITALOPRAM TABLETS 20MG,BATCH NO.ET22099 | $50.0K | 1 |
| CITALOPRAM TABLETS 20MG,BATCH NO.ET22104 | $50.0K | 1 |
| CITALOPRAM TABLETS 20MG,BATCH NO.ET22109 | $50.0K | 1 |
WAYMADE PLC imports 55 distinct Citalopram formulations from India. The top formulation is CITALOPRAM TABLETS 10MG,BATCH NOS.ET2300 with 3 shipments worth $150.0K.
Regulatory Requirements: Importing Citalopram into United Kingdom
What WAYMADE PLC and other importers must comply with to import Citalopram from India
Regulatory Authority
Medicines and Healthcare products Regulatory Agency (MHRA)
Approval Process for Generic Citalopram
Marketing Authorisation via national procedure or Mutual Recognition. Post-Brexit, separate UK MA required independent of EU approval.
Typical timeline: 12–15 months for national procedure
GMP Requirements
UK GMP compliance; MHRA GMP inspection of manufacturing site
Import Licence & Documentation
Manufacturer/Importer Authorisation (MIA) from MHRA; Qualified Person release required
Labeling & Packaging
UK-specific labeling; English language PIL; UK Marketing Authorisation number
Note: Post-Brexit, EU GMP certificates no longer automatically valid — separate MHRA recognition required.
Regulatory information is provided for general reference based on publicly available MHRA guidelines for pharmaceutical imports. Requirements may vary by specific drug formulation, dosage form, and therapeutic classification. Importers should consult directly with MHRA or qualified regulatory affairs professionals for case-specific guidance.
Who Are the Top Buyers of Citalopram from India and How Much Does WAYMADE PLC Import?
India exported $54.8M worth of Citalopram through 7,372 shipments from 257 suppliers to 101 countries, serving 736 buyers globally. WAYMADE PLC imports $2.6M of this total, accounting for 1.3% of India's Citalopram exports with 64 shipments from UNITED KINGDOM. This is verified from 64 customs shipment records covering 55 distinct formulations.
What Is the Average Order Value for WAYMADE PLC's Citalopram Imports?
WAYMADE PLC's average Citalopram order value is $40.3K per consignment, based on 64 shipments totaling $2.6M. WAYMADE PLC is based in UNITED KINGDOM and ranks #12 among all Citalopram importers from India by value. The company sources from 1 verified supplier in India.
Who Supplies Citalopram to WAYMADE PLC?
WAYMADE PLC sources Citalopram from 1 verified Indian supplier: GALPHA LABORATORIES LIMITED ($2.6M, 100.0%). This is based on 64 customs records.
How Does WAYMADE PLC Compare to Other Citalopram Importers?
WAYMADE PLC ranks #12 among 736 Citalopram importers from India with a 1.3% market share. The top 3 importers are YUSEN LOGISTICS BENELUX BELGIUM ($8.9M), TORRENT PHARMA INC ($7.3M), LEK S.A. ($4.1M). WAYMADE PLC processed 64 shipments from UNITED KINGDOM.
About WAYMADE PLC
WAYMADE PLC imports 2 products worth $4.2M. Beyond Citalopram, top products include Hydrocortisone. View the complete WAYMADE PLC profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Citalopram — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- European Medicines Agency
- WHO Essential Medicines
- Invest India — Pharma Sector
- India Trade Statistics (DGFT)
Verify import regulations and drug registration requirements with the agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Citalopram shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature and HS code classification.
- 2.Buyer Identification: WAYMADE PLC matched across shipments using first-3-word normalization of the consignee field, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort buyer rankings.
- 4.Market Share: Calculated as WAYMADE PLC's capped import value divided by total capped export value for Citalopram across all Indian exporters.
- 5.Verified Records: This page is backed by 64 individual customs records matching WAYMADE PLC importing Citalopram, covering 55 formulations from 1 verified supplier.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 101+ countries, 736+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Citalopram Import Data for WAYMADE PLC
Access order-level details, pricing data, supplier connections, and competitive analysis for WAYMADE PLC's Citalopram imports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
WAYMADE PLC
Full Company Profile →
2 products · $4.2M total trade · 2 categories
WAYMADE PLC × Citalopram
Verified from customs records
Company Overview
Top Products by WAYMADE PLC
Related Analysis
Need Detailed Import Data?
Access shipment-level records, supplier contacts, and formulation details for WAYMADE PLC.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Citalopram. For current order-level data, contact TransData Nexus.